Can zapping the brain sharpen fading memory?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Both Veterans and Non-Veterans may enroll if they meet the following criteria \*\* Inclusion Criteria: * Diagnosed with amnestic Mild Cognitive Impairment (aMCI); * Stable medications (including any dementia-related meds) for at least 4 weeks prior to Baseline; * Geriatric Depression Scale score less than 6; * Ability to obtain a motor threshold, determined during the screening process; * Study partner available; living situation enables attendance at clinic visits; * Visual and auditory acuity adequate for neuropsychological testing; * Good general health with no diseases expected to interfere with the study; * Participant is not pregnant or of childbearing potential (i.e. women must be 2 years post-menopausal or surgically sterile); * Modified Hachinski Ischemic score less than or equal to 4; * Agree to DNA extraction for single nucleotide polymorphism (SNP) genotyping; * Able to understand study procedures and comply with them for the entire length of the study. Exclusion Criteria: * Prior exposure to rTMS within the past 12 months; * Magnetic field safety concern such as a cardiac pacemaker, cochlear implant, implanted device in the brain (deep brain stimulation), or metal fragments or foreign objects in the eyes, skin or body; * Any significant neurological disease other than suspected incipient Alzheimer's disease; * Unstable cardiac disease or recent (\< 3 months previous) myocardial infarction. Any significant systemic illness or unstable medical condition that could lead to difficulty with protocol adherence; * History of epilepsy or repetitive seizures, as determined by patient report or chart review; * History of a medical condition or current use/abuse of medications and substances that increase the risk of a seizure, specifically: * Traumatic brain injury within 2 months that would increase the risk for seizure; * Unable to safely withdraw, at least 4 weeks prior to Baseline, from medications that substantially increase the risk of having seizures (for example: theophylline, clozapine, and methylphenidate). * Current or past history of a mass lesion, cerebral infarct, or other noncognitive active neurological disease that would increase the risk for seizure. * Stimulant abuse within the previous 90 days. Cocaine and abuse of amphetamine and methylphenidate are associated with an increased risk of seizures; * Major depression or bipolar disorder (DSM-IV) within the past 1 year, or psychotic features within the last 3 months that could lead to difficulty with protocol adherence; * Taking sedative hypnotics or medications with anti-cholinergic properties and unable to withdraw at least 4 weeks prior to Baseline; * Current alcohol or substance abuse (not including caffeine or nicotine) within the past 1 year, as determined by chart review, participant or study partner report, or greater than "moderate" alcohol use defined by the Quantity-Frequency-Variability Index (Cahalan, Cisin, \& Crossley, 1969); * Any contraindications for magnetic resonance imaging (MRI) studies, e.g. severe claustrophobia, weight above 350 lb maximum allowed by MRI scanner, pregnancy; * Participation in another concurrent clinical trial; * Inability or unwillingness of individual or legal representative to give written informed consent.